Upadacitinib
Products Upadacitinib was approved in the US and EU in 2019 and in many countries in 2020 in extended-release tablet form (Rinvoq sustained-release tablets). Structure and properties Upadacitinib (C17H19F3N6O, Mr = 380.4 g/mol) exists in the drug as a hemihydrate. Effects Upadacitinib has selective immunosuppressive and anti-inflammatory properties. The effects are due to selective and … Upadacitinib